中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 129-134

Value of lipid accumulation product and visceral fat index in predicting nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.01.020
  • 1.

    Graduate School of Beijing University of Chinese Medicine, Beijing 100029, China

  • 2a.

    Department of Neurology, China-Japan Friendship Hospital, Beijing 100029, China

  • 2b.

    Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, China

  • 3.

    Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

  • Received Date: 2021-06-21
  • Accepted Date: 2021-07-08
  • Published Date: 2022-01-20
    Abstract
  •   Objective  To investigate the association of lipid accumulation product (LAP) and visceral fat index (VAI) with nonalcoholic fatty liver disease (NAFLD) and the value of LAP and VAI in predicting the risk of NAFLD.  Methods  A total of 708 subjects who underwent physical examination in China-Japan Friendship Hospital from September 2018 to May 2019 were enrolled and divided into NAFLD group (n=426) and non-NAFLD group (n=282), and the two groups were compared in terms of LAP, VAI, and related biochemical parameters. The independent samples t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups.The chi-square test was used for comparison of categorical data between groups. The Spearman test was used for correlation analysis. The subjects were divided into L1-L4 groups based on LAP and V1-V4 groups based on VAI, and the distribution of NAFLD was compared between groups; a logistic regression analysis was used to calculate the risk of NAFLD at different levels of LAP and VAI, and the receiver operating characteristic (ROC) curves were plotted for LAP, VAI, waist circumference (WC), and body mass index (BMI) in predicting NAFLD in different sex and body weight subgroups, so as to evaluate the value of each index in the prediction and diagnosis of NAFLD.  Results  Compared with the non-NAFLD group, the NAFLD group had significantly higher age, proportion of male subjects, proportion of subjects with a smoking history, and levels of LAP, VAI, WC, BMI, systolic blood pressure, diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglyceride, low-density lipoprotein cholesterol, fasting blood glucose, and serum uric acid, as well as a significantly lower level of high-density lipoprotein cholesterol (all P < 0.01). NAFLD was positively correlated with the levels of LAP and VAI (Cramer's V=0.552 and 0.464). The multivariate logistic regression analysis showed that after adjustment for related risk factors, the risk of NAFLD in the L4 group was still 8.811 (95% confidence interval [CI]: 4.335-17.910) times that in the L1 group (P < 0.001), and the risk of NAFLD in the V4 group was still 5.967 (95% CI: 3.263-10.912) times than that in the V1 group (P < 0.001). The ROC curve analysis showed that both LAP and VAI had an area under the ROC curve (AUC) of > 0.7 in predicting the onset of NAFLD in different sex and body weight subgroups; the AUCs of LAP and VAI in the female subgroup were significantly higher than those in the male subgroup (LAP: 0.886 vs 0.785, P < 0.05; VAI: 0.824 vs 0.748, P < 0.05), and the corresponding sensitivities and specificities of LAP and VAI in the female subgroup were also higher than those in the male subgroup (sensitivity: LAP: 79.8% vs 63.7%; VAI: 77.9% vs 77.0%; specificity: LAP: 85.0% vs 81.1%; VAI: 77.6% vs 62.3%).  Conclusion  The risk of NAFLD increases with the increase in the levels of LAP and VAI. Both LAP and VAI have a good value in predicting NAFLD in different sex and body weight subgroups, especially in predicting NAFLD in the female population.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367.
    [2]
    SAKLAYEN MG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep, 2018, 20(2): 12. DOI: 10.1007/s11906-018-0812-z.
    [3]
    RINELLA ME. Nonalcoholic fatty liver disease: A systematic review[J]. JAMA, 2015, 313(22): 2263-2273. DOI: 10.1001/jama.2015.5370.
    [4]
    LIU C, ZANG LJ. Research progress of new type body fat indexes of lipid accumulation product index and visceral adiposity index[J]. Chin J Diabetes, 2016, 24(11): 1032-1035. DOI: 10.3969/j.issn.1006-6187.2016.11.16.

    刘晨, 张黎军. 新型体脂指数脂质蓄积指数和内脏脂肪指数的相关研究进展[J]. 中国糖尿病杂志, 2016, 24(11): 1032-1035. DOI: 10.3969/j.issn.1006-6187.2016.11.16.
    [5]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [6]
    ZHANG Y, LI B, LIU N, et al. Evaluation of different anthropometric indicators for screening for nonalcoholic fatty liver disease in elderly individuals[J]. Int J Endocrinol, 2021, 2021: 6678755. DOI: 10.1155/2021/6678755.
    [7]
    VURAL KESKINLER M, MUTLU HH, SIRIN A, et al. Visceral adiposity index as a practical tool in patients with biopsy-proven nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Metab Syndr Relat Disord, 2021, 19(1): 26-31. DOI: 10.1089/met.2020.0054.
    [8]
    DAI H, WANG W, CHEN R, et al. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults[J]. Nutr Metab (Lond), 2017, 14: 49. DOI: 10.1186/s12986-017-0206-2.
    [9]
    ÖZCAB1 B, DEMIRHAN S, AKYOL M, et al. Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity[J]. Korean J Pediatr, 2019, 62(12): 450-455. DOI: 10.3345/kjp.2019.00248.
    [10]
    OKAMURA T, HASHIMOTO Y, HAMAGUCHI M, et al. The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study[J]. Clin Res Hepatol Gastroenterol, 2020, 44(3): 375-383. DOI: 10.1016/j.clinre.2019.04.002.
    [11]
    XU C, MA Z, WANG Y, et al. Visceral adiposity index as a predictor of NAFLD: A prospective study with 4-year follow-up[J]. Liver Int, 2018, 38(12): 2294-2300. DOI: 10.1111/liv.13941.
    [12]
    VONGSUVANH R, GEORGE J, MCLEOD D, et al. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2012, 57(2): 392-398. DOI: 10.1016/j.jhep.2012.03.013.
    [13]
    CASTERA L, FRIEDRICH-RUST M, LOOMBA R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156(5): 1264-1281. e4. DOI: 10.1053/j.gastro.2018.12.036.
    [14]
    ZHOU YJ, ZHOU YF, ZHENG JN, et al. NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver[J]. Clin Chim Acta, 2017, 475: 44-50. DOI: 10.1016/j.cca.2017.09.020.
    [15]
    YIP TC, MA AJ, WONG VW, et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population[J]. Aliment Pharmacol Ther, 2017, 46(4): 447-456. DOI: 10.1111/apt.14172.
    [16]
    GHOSH A, GAO L, THAKUR A, et al. Role of free fatty acids in endothelial dysfunction[J]. J Biomed Sci, 2017, 24(1): 50. DOI: 10.1186/s12929-017-0357-5.
    [17]
    LONGO M, ZATTERALE F, NADERI J, et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications[J]. Int J Mol Sci, 2019, 20(9): 2358. DOI: 10.3390/ijms20092358.
    [18]
    XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.

    薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (907) PDF downloads(103) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return